Income Investing Insider
  • Economy
  • Business
  • Investing
  • Stock
No Result
View All Result
  • Economy
  • Business
  • Investing
  • Stock
No Result
View All Result
Income Investing Insider
No Result
View All Result
Home Stock

Moderna cuts 2025 revenue to $2.2B after UK booster delay

August 2, 2025
in Stock
Moderna cuts 2025 revenue to $2.2B after UK booster delay

Moderna has lowered the high end of its 2025 revenue forecast, citing a delay in Covid vaccine shipments to the UK. The company now expects between $1.5 billion and $2.2 billion in revenue, down $300 million at the top of its earlier range.

The adjustment comes as Moderna continues to face dwindling Covid vaccine demand, while also moving forward with cost-cutting efforts, including a 10% workforce reduction.

Despite this, Moderna reported second-quarter revenue and earnings results that beat Wall Street expectations, with losses coming in smaller than anticipated.

Revenue guidance lowered as UK shipment pushed to 2026

On Friday, Moderna confirmed that instead of delivering spring Covid boosters to the UK at the end of 2025, the doses will now be shipped in the first quarter of 2026.

The company stated that the overall contract value with the UK government remains unchanged, but the timing of the delivery has shifted to align with the UK’s fiscal year-end.

As a result, the company reduced its annual revenue outlook by $300 million. Full-year guidance now sits between $1.5 billion and $2.2 billion, as compared with its earlier projection of up to $2.5 billion.

Shares of Moderna fell more than 6% in premarket trading on Friday following the announcement.

Second-quarter sales fall 41% year over year

For the second quarter, Moderna reported $142 million in revenue, which was higher than the $113 million analysts expected, according to data from LSEG.

However, sales were still down 41% compared with the same period last year, reflecting the ongoing decline in Covid vaccine demand.

The vast majority of the second-quarter revenue—$114 million—came from Moderna’s Covid shot. This exceeded analyst forecasts of $89 million, based on StreetAccount estimates.

The company’s respiratory syncytial virus (RSV) vaccine, meanwhile, posted negligible sales, far below the $5.9 million expected.

Net loss narrows as operating expenses reduced by 27%

Moderna posted a net loss of $825 million, or $2.13 per share, for the quarter. This compares with a net loss of $1.3 billion, or $3.33 per share, in the year-ago period.

Analysts had expected a larger quarterly loss of $2.97 per share, meaning Moderna’s results were better than anticipated.

The company attributed this outperformance in part to cost controls. Operating expenses dropped 27% year on year, from $1.6 billion to $1.1 billion.

Executives emphasised that expense management has been critical to supporting Moderna’s financials as Covid vaccine sales continue to decline.

Workforce reduction and cost management strategy

The updated revenue outlook came a day after Moderna announced plans to cut its workforce by 10%.

This move adds to a series of cost-cutting measures the company has implemented in response to weaker Covid-related sales.

The workforce reduction and expense cuts are aimed at helping Moderna sustain investment in new products while managing reduced revenue streams.

While the company’s Covid shot remains the largest contributor to revenue, Moderna continues to focus on broadening its pipeline, including vaccines targeting flu and RSV.

However, with negligible RSV sales in the second quarter, the company remains reliant on Covid boosters for the majority of its income.

The post Moderna cuts 2025 revenue to $2.2B after UK booster delay appeared first on Invezz

Previous Post

Brazil antitrust watchdog probes Microsoft after Opera complaint over edge browser practices

Next Post

US stock plunge as jobs data disappoints and tariff tensions rise

    Join our mailing list to get access to special deals, promotions, and insider information. Your exclusive benefits await! Enjoy personalized recommendations, first dibs on sales, and members-only content that makes you feel like a true VIP. Sign up now and start saving!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Disclaimer: incomeinvestinginsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Recent News

    Amazon shares fall more than 8% premarket as AWS growth disappoints investors

    Amazon shares fall more than 8% premarket as AWS growth disappoints investors

    August 2, 2025
    BYD’s July sales stall, casting doubt on 2025 delivery target

    BYD’s July sales stall, casting doubt on 2025 delivery target

    August 2, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms and Conditions
    • Email Whitelisting

    Copyright © 2025 incomeinvestinginsider.com | All Rights Reserved

    No Result
    View All Result
    • About us
    • Contacts
    • Email Whitelisting
    • Home 1
    • Privacy Policy
    • Terms and Conditions
    • Thank you

    Copyright © 2025 incomeinvestinginsider.com | All Rights Reserved